Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-105258
Filing Date
2024-12-04
Accepted
2024-12-04 08:32:44
Documents
3
Period of Report
2024-12-04

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0223584-6k_neurosense.htm 6-K 11962
2 PRESS RELEASE, DATED DECEMBER 4, 2024, ENTITLED "NEUROSENSE ANNOUNCES COMPLETION ea022358401ex99-1_neurosense.htm EX-99.1 17615
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2708
  Complete submission text file 0001213900-24-105258.txt   34519
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 241524940
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)